Login to Your Account

Chi-Med, AZ complete phase II enrollment in largest PRCC kidney cancer trial to date

By Shannon Ellis
Staff Writer

Thursday, October 15, 2015

SHANGHAI – Hutchison Medipharma Ltd. with its partner Astrazeneca plc, enrolled 90 patients at 22 sites in a global phase II trial for savolitinib in papillary renal cell carcinoma, a type of cancer that afflicts about 14 percent of new cases of kidney cancer in the world.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription